A systematic framework for prioritising burden of disease data required for vaccine development and implementation: the case for group A streptococcal diseases

Vaccine development and implementation decisions need to be guided by accurate and robust burden of disease data. We developed an innovative systematic framework outlining the properties of such data that are needed to advance vaccine development and evaluation, and prioritise research and surveillance activities. We focus on four objectives: advocacy; regulatory oversight and licensure; policy and post-licensure evaluation; and post-licensure financing and identify key stakeholders and specific requirements for burden of disease data aligned with each objective. We apply this framework to group A Streptococcus, a pathogen with an under-recognised global burden, and give specific examples pertinent to eight clinical endpoints. This dynamic framework can be adapted for any disease with a vaccine in development and can be updated as vaccine candidates progress through clinical trials. This framework will also help with research and innovation priority setting of the Immunization Agenda 2030 (IA2030) and accelerate development of future vaccines.